Abstract Number: 2654 • 2017 ACR/ARHP Annual Meeting
Treatment-Associated DNA Methylation Patterns in Systemic Lupus Erythematosus
Background/Purpose: DNA methylation has emerged as an important contributing factor in the pathogenesis of systemic lupus erythematosus (SLE). SLE typically requires continuous treatment to control…Abstract Number: 2812 • 2017 ACR/ARHP Annual Meeting
Healthcare Resource Utilization and Costs in Patients with Systemic Lupus Erythematosus before and after Initiating Treatment with Intravenous Belimumab: A US Claims Database Analysis
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. There is…Abstract Number: 765 • 2016 ACR/ARHP Annual Meeting
High Baseline B Lymphocyte Stimulator (BLyS) Levels Predict Response While Smoking and Organ Damage at Baseline Predict Failure to Belimumab in Three Swedish Clinical Practice Settings
Background/Purpose: Belimumab is a biologic drug approved to treat Systemic Lupus Erythematosus (SLE). The efficacy of belimumab has been demonstrated in phase III clinical trials.…Abstract Number: 792 • 2016 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate to Severe SLE
Background/Purpose: Post-hoc analysis of two Phase III studies of belimumab1 showed that an SRI(4) response is associated with clinically meaningful benefits, irrespective of treatment assignment.…Abstract Number: 1806 • 2016 ACR/ARHP Annual Meeting
Adherence to Treatment and Social, Educational Levels in Patients with Systemic Lupus Erythematosus
Background/Purpose: To assess adherence to treatment in patients with Systemic Lupus Erythematosus (SLE) and to determine its relationship with social, educational levels and disease activity.…Abstract Number: 2009 • 2016 ACR/ARHP Annual Meeting
The Effect of Anifrolumab on Cutaneous Manifestations and Arthritis in Moderate to Severe Systemic Lupus Erythematosus (SLE) Using Categorical SLEDAI–2K Responses and Continuous Measures of Activity As Outcome Measures
Background/Purpose: The Phase IIb MUSE study (NCT01438489) of intravenous anifrolumab in 305 patients with moderate to severely active SLE (300 or 1,000 mg vs. placebo,…Abstract Number: 2852 • 2016 ACR/ARHP Annual Meeting
Long Term Prognosis of Lupus Nephritis in the Afro-Caribbean Population of Martinique with Free Access to Healthcare
Background/Purpose: In African-descent patients, lupus nephritis (LN) lead to a worse outcome than in Caucasians. Long term data are rare in countries where black populations…Abstract Number: 3219 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of 4 Weeks Administration of Arsenic Trioxide in Moderate Active Systemic Lupus Erythematosus. a Phase I/II Proof-of-Concept Sequential Dose Escalation Multicenter Study
Background/Purpose: Arsenic Trioxide (ATO) is approved for the treatment of acute promyelocytic leukemia, increasing oxidative stress with selective apoptosis of leukemia cells. In MLR/lpr model…Abstract Number: 3221 • 2015 ACR/ARHP Annual Meeting
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multi-system involvement, associated with an imbalance between effector and regulatory CD4+ T cells. The…Abstract Number: 665 • 2014 ACR/ARHP Annual Meeting
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to nuclear self-antigens, production of pathogenic autoantibodies and damage tomultiple organs.…Abstract Number: 2624 • 2014 ACR/ARHP Annual Meeting
Impact of Provider Specialty on the Diagnosis and Management of Systemic Lupus Erythematosus in the American Indian/Alaska Native Population
Background/Purpose Systemic lupus erythematosus (SLE) is a complex disease that is traditionally diagnosed and managed by specialists, typically rheumatologists. Higher SLE prevalence in racial/ethnic minorities…Abstract Number: 2623 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns and Resource Utilization of Systemic Lupus Erythematosus Patients Newly Initiating Standard of Care: United States Commercial and Medicare Supplemental Claims Analysis
Background/Purpose: Currently, there is not a standard treatment algorithm for the management of Systemic Lupus Erythematosus (SLE); however, there are medications that may be considered…Abstract Number: 1857 • 2014 ACR/ARHP Annual Meeting
Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use
Background/Purpose: Newer therapeutic agents in systemic lupus erythematosus (SLE) may increase cost of care but their effect on limiting the duration and the dosage of…Abstract Number: 1666 • 2014 ACR/ARHP Annual Meeting
The Relevance of Urinary Podocyte Number and Urinary Podocalyxin Level with Response to Treatment and 1 Year Renal Prognosis in Systemic Lupus Erythematosus
Background/Purpose Podocytes are glomerular visceral epithelial cells, whose number decrease due to death and/or detachment from capillary wall leads to severe proteinuria and end stage…Abstract Number: 1663 • 2014 ACR/ARHP Annual Meeting
Influence of Ethnicity on Efficacy of Current Immunosuppressive Protocols in Proliferative Lupus Nephritis
Background/Purpose Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and prevalence is estimated to be 50-60%. Recently, variable responses to induction…
ACR Meeting Abstracts